Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Gleevec (STI571)
Before treatment starts, patients will have a physical exam including medical history and
documentation of disease, blood tests, and a bone marrow study. The bone marrow will be
removed with a large needle.
Patients on this study will take 400 mg of imatinib daily (morning or evening). If you have
side effects, the dose may be lowered. If the response is not good, the dose of imatinib
mesylate will be increased to 800 mg daily (400 mg in the morning and 400 mg in the evening)
or may be decreased to 300 mg daily based on how the drug is tolerated. Imatinib mesylate
should be taken with a large glass of water. Bottles containing the tablets will be given
to the patient every 6 months. Unused supplies must be returned at the end of the study.
After completing 3 to 12 months of therapy, response to imatinib mesylate will be evaluated.
If the response is good, treatment with imatinib mesylate alone will be continued.
Treatment may be continued for up to 20 years, or as long as it is judged best to control
Update: June 2010:
Blood tests are recommended 2 times per year. Your doctor will discuss with you how often
you should have blood tests. Bone marrow will be done if your doctor thinks it is necessary
to check your disease. You must return to MD Anderson at least once every year. You may not
need a bone marrow test every visit, but you will have blood drawn to measure the amount of
disease you have. If the leukemia cannot be found for 2 years or longer on the blood test
called PCR which is done to measure the amount of disease you have, your doctor may talk to
you about stopping treatment with imatinib. If you and your doctor decide to stop your
therapy, you will have a blood test for PCR done every 3 to 6 months. You do not need to
return to MD Anderson to have this blood test done. You may have the blood taken by your
local doctor and mailed to MD Anderson. If the leukemia is found again by the PCR blood
test, your doctor may recommend that you restart treatment with imatinib. You may decide to
stay on treatment with imatinib even if your PCR blood test does not show any sign of
leukemia for 2 years or longer.
This is an investigational study. Imatinib mesylate has been approved in CML. A total of
50 patients will take part in this study. All will be enrolled at MD Anderson.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of patients achieving complete cytogenetic response using initial Gleevec therapy
Baseline to 12 Months
Jorge E Cortes, MD
M.D. Anderson Cancer Center
United States: Food and Drug Administration
|UT MD Anderson Cancer Center||Houston, Texas 77030|